L'intérêt à découvert pour Alnylam Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Alnylam Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock, Rapport sur les intérêts à découvert

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

Biotech

News

Health Care

General

ALNY

The FDA Has Alnylam Pharmaceuticals' Supplemental Marketing Application For Vutrisiran For ATTR Amyloidosis With Cardiomyopathy, Based On The Company's Use Of A Priority Review Voucher, FDA Has Set An Action Date Goal Of March 23, 2025

Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) revealed 11 unusual trades.
Delving into the details, we found 27% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $515,770, and 2 were calls, valued at $88,650.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $210.0 to $290.0 for Alnylam Pharmaceuticals during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Alnylam Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Alnylam Pharmaceuticals's significant trades, within a strike price range of $210.0 to $290.0, over the past month.
<h3>Alnylam Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732049153_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$15.5</td>
<td>$240.00</td>
<td>$130.2K</td>
<td align="right">517</td>
<td align="right">100</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.0</td>
<td>$3.5</td>
<td>$210.00</td>
<td>$62.6K</td>
<td align="right">170</td>
<td align="right">457</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$58.5</td>
<td>$55.9</td>
<td>$57.0</td>
<td>$290.00</td>
<td>$57.0K</td>
<td align="right">241</td>
<td align="right">40</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$54.0</td>
<td>$50.5</td>
<td>$54.0</td>
<td>$250.00</td>
<td>$54.0K</td>
<td align="right">0</td>
<td align="right">10</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$50.1</td>
<td>$46.6</td>
<td>$48.1</td>
<td>$280.00</td>
<td>$52.9K</td>
<td align="right">395</td>
<td align="right">11</td>
</tr>
</tbody>
</table>

<h3>About Alnylam Pharmaceuticals</h3>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
In light of the recent options history for Alnylam Pharmaceuticals, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Alnylam Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a volume of 446,657, the price of ALNY is up 0.74% at $233.99. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 86 days.</li>
</ul>
<h3>What Analysts Are Saying About Alnylam Pharmaceuticals</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $350.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Alnylam Pharmaceuticals, targeting a price of $384. 
&#x2A; An analyst from Piper Sandler downgraded its action to Overweight with a price target of $296. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $400. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $300. 
&#x2A; An analyst from TD Cowen persists with their Buy rating on Alnylam Pharmaceuticals, maintaining a target price of $371. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Alnylam Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

This Is What Whales Are Betting On Alnylam Pharmaceuticals

Piper Sandler analyst Edward Tenthoff reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Overweight and maintains $296 price target.

Price Target

Reiteration

Analyst Ratings

Piper Sandler Reiterates Overweight on Alnylam Pharmaceuticals, Maintains $296 Price Target

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

<ul>
<li>Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months&nbsp;</li>
<li>At These Doses, Peak Reduction of Mean TTR Levels of Greater than 96% were Achieved by Day 29 −</li>
<li>Data Support Potential for Biannual or Annual Subcutaneous Dosing, Representing a New Paradigm in the Treatment of ATTR Amyloidosis −</li>
<li>Encouraging Safety and Tolerability Observed −</li>
<li>Alnylam Continues to Expect to Share Phase 3 Development Plans in Q1 2025 –</li>
</ul>

Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose

WIIM

Alnylam Pharmaceuticals shares are trading lower after Wolfe Research downgraded the stock from Peer Perform to Underperform.

During the last three months, 24 analysts shared their evaluations of Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $322.83, a high estimate of $400.00, and a low estimate of $220.00. Surpassing the previous average price target of $306.57, the current average has increased by 5.3%.
<img src="https://www.benzinga.com/files/images/story/2024/1731412824_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$298.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$310.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$329.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$366.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$371.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$314.00</td>
<td>$307.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$307.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$248.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$198.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Alnylam Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Alnylam Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Alnylam Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Alnylam Pharmaceuticals</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Understanding the Numbers: Alnylam Pharmaceuticals's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Alnylam Pharmaceuticals's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -33.26% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Alnylam Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -22.27%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -761.91%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Alnylam Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.72%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 40.24, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Alnylam Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wolfe Research analyst Andy Chen downgraded the rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) from Peer Perform to Underperform. Alnylam Pharmaceuticals shares closed at $279.82 on Monday. <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Phillip Securities downgraded the rating for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from Neutral to Reduce and announced a $120 price target. Airbnb shares closed at $137.40 on Monday. <a href="https://www.benzinga.com/quote/ABNB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Scott Buck downgraded Phunware, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) from Buy to Neutral and lowered the price target from $9 to $6. Phunware shares closed at $5.99 on Monday. <a href="https://www.benzinga.com/quote/PHUN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Brad Zelnick downgraded Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Buy to Hold and lowered the price target from $115 to $85. Okta shares closed at $78.45 on Monday. <a href="https://www.benzinga.com/quote/OKTA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst Meyer Shields downgraded the rating for Horace Mann Educators Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMN#NYSE">HMN</a>) from Outperform to Market Perform and raised the price target from $39 to $44. Horace Mann Educators shares closed at $42.31 on Monday. <a href="https://www.benzinga.com/quote/HMN/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ABNB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12063222/image-119-1024x571.png" alt="" class="wp-image-642538" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12063222/image-119-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12063222/image-119-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12063222/image-119-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/12063222/image-119.png 1187w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></li>
</ul>

Downgrades

Pre-Market Outlook

Trading Ideas

ABNB

MRCY

OKTA

PHUN

UEIC

This Airbnb Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Wolfe Research analyst Andy Chen downgrades Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) from Peer Perform to Underperform.

Wolfe Research Downgrades Alnylam Pharmaceuticals to Underperform

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve&#8217;s interest rate cuts in September. 
According to GlobalData, the top 20 global biopharmaceutical companies <a href="https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-witness-2-growth-in-market-capitalization-in-q3-2024-reveals-globaldata/#:~:text=As%20a%20result%2C%20the%20top,data%20analytics%20and%20research%20company.">saw</a> a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. 
This rebound highlights the industry&#8217;s potential for growth despite challenges earlier in the year.
Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) led the market with the largest increase in capitalization, which surged by 24.6% to $105 billion. This was largely driven by advancements in its pipeline, notably the FDA&#8217;s approval of its antipsychotic drug, Cobenfy, for treating <a href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea">schizophrenia in September 2024</a>. 
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost">posted impressive growth</a>, rising 22.1% in market value, thanks to the accelerated FDA approval of Livdelzi, a treatment for <a href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal">primary biliary cholangitis</a>, as well as the approval of its antibody-drug conjugate, Trodelvy, for HR-/HER2- breast cancer in Japan.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) experienced a 19.2% jump in market capitalization, largely fueled by its <a href="https://www.benzinga.com/general/biotech/24/10/41541274/sanofi-earns-5b-q3-core-profit-on-strong-dupixent-and-vaccine-sales-raises-2024-forecast">flagship drug Dupixent</a>. The drug&#8217;s strong performance in the treatment of conditions such as asthma and atopic dermatitis, coupled with its recent EMA and FDA approvals for chronic obstructive pulmonary disease (COPD), further <a href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease">boosted Sanofi&#8217;s standing</a>. 
Similarly, AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) saw a 15.2% increase in its market cap, driven by the continued success of its immunology drugs—Humira, Skyrizi, and Rinvoq—which together generated nearly $7 billion <a href="https://www.benzinga.com/general/biotech/24/07/39960414/abbvies-q2-earnings-beat-estimates-raises-annual-profit-on-strong-sales-from-newer-immunology-and">in Q2 2024 sales</a>.
Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) joined the top 20 biopharmaceutical companies with a 14.9% rise in its market value, following its RNAi drug vutrisiran's positive results in treating ATTR <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">amyloidosis with cardiomyopathy</a>. 
Roche Holdings AG's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) market capitalization grew by 13.8%, spurred by the FDA&#8217;s approval of two key products, Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for oncology indications, the latter being the only approved subcutaneous <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">PD-L1 inhibitor available</a>.
On the downside, Wegovy maker Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) saw an 18.2% drop in its market cap after the FDA rejected its BLA filing for the once-<a href="https://www.benzinga.com/general/biotech/24/07/39732571/fda-rejects-novo-nordisks-weekly-insulin-requests-information-related-to-manufacturing-process-ty">weekly insulin icodec</a>.
Similarly, Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) reported a slight decline of 2.1%, though both companies retained their leadership in diabetes and <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">weight loss drugs</a>. 
Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) also faced a 8.2% fall in market value, largely due to disappointing sales of its HPV vaccine, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41693101/mercks-gardasil-shot-challenges-to-continue-analysts-optimistic-for-newly-approved-">Gardasil, in China</a>.
&nbsp;"The biopharmaceutical industry is poised for a recovery, fueled by multiple FDA approvals leading to a rebound in companies that have seen declines in market capitalization in previous quarters, such as Gilead Sciences and Bristol-Myers Squibb,&#8221; says GlobalData analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41853302/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-heres-why">ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside &#8211; Here&#8217;s Why</a></li>
</ul>
Image Via Shutterstock

Large Cap

Movers

ABBV

GILD

RHHBY

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

In the last three months, 24 analysts have published ratings on Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $322.83, a high estimate of $400.00, and a low estimate of $220.00. This current average has increased by 5.3% from the previous average price target of $306.57. 
<img src="https://www.benzinga.com/files/images/story/2024/1730746808_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Alnylam Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Gary Nachman</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$298.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$310.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$329.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$384.00</td>
<td>$366.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$371.00</td>
<td>$282.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$314.00</td>
<td>$307.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$307.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$248.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$198.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alnylam Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Alnylam Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Alnylam Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Alnylam Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Alnylam Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Alnylam Pharmaceuticals Better</h2>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Alnylam Pharmaceuticals: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Alnylam Pharmaceuticals's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -33.26%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Alnylam Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -22.27%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Alnylam Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -761.91%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.72%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 40.24, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (24 Ratings)

Raymond James analyst Gary Nachman maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $275 to $298.

Raymond James Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $298

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and maintains $300 price target.

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target

Scotiabank analyst Greg Harrison maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Sector Outperform and raises the price target from $305 to $310.

Scotiabank Maintains Sector Outperform on Alnylam Pharmaceuticals, Raises Price Target to $310

Barclays analyst Gena Wang maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Overweight and raises the price target from $295 to $329.

Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $329

Canaccord Genuity analyst Whitney Ijem maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $366 to $384.

Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $384

Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $300 price target.

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $300 Price Target

Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $320 price target.

Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has risen 7.43% since its last report. The company recently reported that it has 4.84 million shares sold short, which is 4.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730403932_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.14%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest

In a report released yesterday, Michael Ulz from Morgan Stanley maintained a Hold rating on Alnylam Pharma (ALNY – Research Report), with a price t...

Alnylam's Balanced Prospects: Hold Rating Amid Promising Nucresiran Data and Strategic Focus on Vutrisiran

Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

Alnylam Pharma's Promising TTR RNAi Program and Strategic Advancements Drive Buy Rating with $400 Price Target

Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ALNY stock, giving a Hold rating on November 17. Mani Foroohar has gi...

Cautious Outlook on Alnylam Pharma Amid Competitive and Regulatory Challenges

Fidelity Select Health Care Portfolio Q3 2024 Fund Review

Franklin Biotechnology Discovery Fund Q3 2024 Commentary

Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby

BridgeBio: Next Chapter Begins After Attruby Approval

Alnylam (ALNY) Pharmaceuticals announced that the U.S. Food and Drug Administration or FDA, has accepted for review the Company's supplemental New ...

FDA accepts Alnylam's sNDA  for vutrisiran for ATTR-CM treatment

Alnylam Pharma (ALNY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Biliouris from...

Alnylam Pharma: Strong Buy Rating Backed by Regulatory Success and Diverse RNAi Portfolio

APGE

APLT

AQST

ARGNF

ARGX

BAYRY

BAYZF

BBIO

BNTC

CNTA

EXAS

HLVX

HRTX

IONS

KYKOY

MRNA

MRUS

NBIX

NTLA

PCVX

PODD

PRAX

PTCT

REGN

RVNC

SPRY

Press Releases

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results

Alnylam Canada Signs Letter of Intent from pan-Canadian Pharmaceutical Alliance for the Public Reimbursement of AMVUTTRA® For The Treatment Of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis In Adults

Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Comments

Alnylam Pharmaceuticals

Intérêt court

Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL